Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alder Biopharmaceuticals has announced dosing of first patients with migraine in proof-of-concept Phase 2 study evaluating ALD403, an antibody therapeutic candidate targeting calcitonin gene-related peptide (CGRP).
Subscribe to our email newsletter
The double-blind, randomised study will assess the safety and efficacy profile of ALD403 administered monthly.
The Montefiore Headache Center director, Albert Einstein College of Medicine professor of neurology and epidemiology and principal investigator Richard Lipton said, "A biologic targeting CGRP and offering higher rates of efficacy, along with less frequent dosing and fewer side effects, could have a tremendous benefit for patients."
A total of 160 patients with frequent, episodic migraines will be enrolled in the placebo-controlled study across six sites for sixmonths.
Alder president and chief executive officer Randall Schatzman said, "The preventative approach has been welcomed by patients, evidenced by the significant patient interest at all of our trial sites, and we are proud to advance ALD403 into a proof-of-concept trial while exploring additional applications for our core technologies with therapeutic candidates in other disease areas."